前列腺癌局部治疗的研究进展

doi:10.6040/j.issn.1671-7554.0.2018.1067

摘要/Abstract

摘要： 局限性前列腺癌的局部治疗效果已被初步验证,其具有减少不良反应和医疗负担、降低手术或放疗成本的潜力。在新的治疗背景下,其他实体瘤多采用微创的治疗模式。回顾局限性前列腺癌现有的局部治疗方法、效果和研究进展,寻找保留组织的局部治疗方案。

关键词: 前列腺癌, 局部治疗, 冷冻疗法, 高强度聚焦超声, 光动力学疗法

Abstract: Focal therapy for localized prostate cancer has been proved effective and also has the potential to reduce side effects, medical burden, and the costs associated with treatments such as surgery or radiation therapy. This article reviews existing focal treatment methods, effects and research advances and looks for a tissue-preserving focal therapy, which is a minimally invasive treatment followed by most of other solid tumor treatment models.

Key words: Prostate cancer, Focal therapy, Cryotherapy, High intensity focused ultrasound, Photodynamic therapy

中图分类号:

R737.3

吕家驹,胡佳林,丁森泰. 前列腺癌局部治疗的研究进展[J]. 山东大学学报 (医学版), 2019, 57(1): 1-5.

LÜ Jiaju, HU Jialin, DING Sentai. Advances in focal therapy for prostate cancer[J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 1-5.

参考文献

[1] Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer[J]. N Engl J Med, 2014, 370(10): 932-942.
[2] King MT, Viney R, Smith DP, et al. Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer[J]. Br J Cancer, 2012, 106(4): 638-645.
[3] Carlsson S, Drevin L, Loeb S, et al. Population-based study of long-term functional outcomes after prostate cancer treatment[J]. BJU Int, 2016, 117(6B): E36-E45.
[4] Guillaumier S, Peters M, Arya M, et al. A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer[J]. Eur Urol, 2018, 74(4): 422-429.
[5] Ahmed HU, Berge V, Bottomley D, et al. Can we deliver randomized trials of focal therapy in prostate cancer?[J]. Nat Rev Clin Oncol, 2014, 11(8): 482-491.
[6] Ahmed HU, Emberton M. Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?[J]. World J Urol, 2008, 26(5): 457-467.
[7] Calio B, Kasson M, Sugano D, et al. Multiparametric MRI: an opportunity for focal therapy of prostate cancer[J]. Semin Roentgenol, 2018, 53(3): 227-233.
[8] Hara R, Jo Y, Fujii T, et al. Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy[J]. Urology, 2008, 71(2): 191-195.
[9] Ahmed HU, Moore C, Emberton M. Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer[J]. Surg Oncol, 2009, 18(3): 219-232.
[10] Lindner U, Lawrentschuk N, Weersink RA, et al. Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy[J]. Eur Urol, 2010, 57(6): 1111-1114.
[11] Moore CM, Pendse D, Emberton M. Photodynamic therapy for prostate cancer-a review of current status and future promise[J]. Nat Clin Pract Urol, 2009, 6(1): 18-30.
[12] You Y, Liang X, Yin T, et al. Porphyrin-grafted lipid microbubbles for the enhanced efficacy of photodynamic therapy in prostate cancer through ultrasound-controlled accumulation[J]. Theranostics, 2018, 8(6): 1665-1677.
[13] Chen Y, Xu S, Squires A, et al. MRI-guided robotically assisted focal laser ablation of the prostate using canine cadavers[J]. IEEE Trans Biomed Eng, 2018, 65(7): 1434-1442.
[14] He MH, Chen L, Zheng T, et al. Potential applications of nanotechnology in urological cancer[J]. Front Pharmacol, 2018, 9: 745. doi:10.3389/fphar.2018.00745
[15] Jung JH, Risk MC, Goldfarb R, et al. Primary cryotherapy for localised or locally advanced prostate cancer[J]. BJU Int, 2018, doi:10.1111/bju.14519.
[16] Grampsas SA, Miller GJ, Crawford ED, et al. Salvage radical prostatectomy after failed transperineal cryotherapy: histologic findings from prostate whole-mount specimens correlated with intraoperative transrectal ultrasound images[J]. Urology, 1995, 45(6): 936-941.
[17] 郭宏骞,林廷升,连惠波,等.局限性前列腺癌冷冻治疗及其进展[J].现代泌尿外科杂志, 2014, 19(8): 499-501. GUO Hongqian, LIN Tingsheng, LIAN Huibo, et al. Advances of cryotherapy for localized prostate cancer[J]. Journal of Modern Urology, 2014, 19(8): 499-501.
[18] Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database(COLD)Registry[J]. BJU Int, 2012, 109(11): 1648-1654.
[19] Bahn D, de Castro Abreu AL, Gill IS, et al. Focal cryotherapy for clinically unilateral low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years[J]. Eur Urol, 2012, 62(1): 55-63.
[20] Hill CR, ter Haar GR. Review article: high intensity focused ultrasound-potential for cancer treatment[J] Br J Radiol, 1995, 68(816): 1296-1303.
[21] Golan R, Bernstein AN, McClure TD, et al. Partial gland treatment of prostate cancer using high-intensity focused ultrasound in the primary and salvage settings: a systematic review[J]. J Urol, 2017, 198(5): 1000-1009.
[22] Ahmed HU, Hindley RG, Dickinson L, et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study[J]. Lancet Oncol, 2012, 13(6): 622-632.
[23] Ahmed HU, Zacharakis E, Dudderidge T, et al. High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series[J]. Br J Cancer, 2009, 101(1): 19-26.
[24] El Fegoun AB, Barret E, Prapotnich D, et al. Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up[J]. Int Braz J Urol, 2011, 37(2): 213-219.
[25] Muto S, Yoshii T, Saito K, et al. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer[J]. Jpn J Clin Oncol, 2008, 38(3): 192-199.
[26] Stone L. Prostate cancer: light, camera, action-photodynamic therapy for low-risk disease[J]. Nat Rev Urol, 2017, 14(3): 134. doi:10.1038/nrurol.2017.1
[27] Azzouzi AR, Barret E, Moore CM, et al. TOOKAD(®)Soluble vascular-targeted photodynamic(VTP)therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer[J]. BJU Int, 2013, 112(6): 766-774.
[28] Azzouzi AR, Vincendeau S, Barret E, et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer(CLIN1001 PCM301): an open-label, phase3, randomised controlled trial.[J]. Lancet Oncol, 2017, 18(2): 181-191.
[29] Lebdai S, Bigot P, Leroux PA, et al. Vascular targeted photodynamic therapy with padeliporfin for low risk prostate cancer treatment: midterm oncologic outcomes[J]. J Urol, 2017, 198(2): 335-344.
[30] Lindner U, Weersink RA, Haider MA, et al. Image guided photothermal focal therapy for localized prostate cancer: phase I trial[J]. J Urol, 2009, 182(4): 1371-1377.
[31] Oto A, Sethi I, Karczmar G, et al. MR imaging-guided focal laser ablation for prostate cancer: phase I trial[J]. Radiology, 2013, 267(3): 932-940.
[32] Valerio M, Dickinson L, Ali A, et al. Nanoknife electroporation ablation trial: a prospective development study investigating focal irreversible electroporation for localized prostate cancer[J]. J Urol, 2017, 197(3 Pt 1): 647-654.
[33] Scheltema MJ, van den Bos W, Siriwardana AR, et al. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer[J]. BJU Int, 2017. doi: 10.1111/bju.13991
[34] Feutren T, Herrera FG. Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review[J]. Prostate Int, 2018, 6(3):75-87.

相关文章 14

[1]	艾星子·艾里,郭铮宇,张晓霏. 子宫腺肌病高强度聚焦超声消融治疗研究进展[J]. 山东大学学报 (医学版), 2022, 60(7): 36-42.
[2]	许振,刁统祥,臧振杰,邵丁昌,张奇,孙鼎琪,傅强. 前列腺特异性抗原同源异构体2及其衍生指标在前列腺癌诊断中的价值[J]. 山东大学学报 (医学版), 2022, 60(6): 51-56.
[3]	孙浩瑜,姜鑫,陈守臻,曲思凤,史本康. 多参数磁共振联合前列腺健康指数对PSA灰区临床有意义前列腺癌的诊断价值[J]. 山东大学学报 (医学版), 2022, 60(6): 46-50.
[4]	史本康,陈守臻,曲思凤,王勇,刘磊. 临床常见快速进展前列腺癌临床特点及研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 110-116.
[5]	徐兵,李勇,刘明,刘永辉. 沉默PRRX1基因表达可增强前列腺癌耐药细胞株PC-3/DTX对多西他赛的敏感性[J]. 山东大学学报 (医学版), 2021, 59(6): 103-110.
[6]	孙鼎琪,傅强,张辉,刘帅,刁统祥,曹庆伟,张克勤. 多参数磁共振与经直肠超声融合前列腺靶向穿刺活检在检测PI-RADS≥3前列腺癌中的临床价值[J]. 山东大学学报 (医学版), 2021, 59(4): 108-113.
[7]	翟红运, 张登禄, 王光杰, 孔峰, 程广辉, 赵升田. 小鼠胚胎干细胞分泌因子对前列腺癌细胞作用的体外研究[J]. 山东大学学报（医学版）, 2015, 53(9): 8-12.
[8]	丁焕1，孙颖1，黎晓晴2，黎莉1. PARP抑制剂联合吉西他滨或多西他赛对雄激素非依赖性前列腺癌PC3细胞增殖的影响[J]. 山东大学学报（医学版）, 2014, 52(1): 33-36.
[9]	高逢彬，司曼飞，刘永青，牛蕾蕾，苑辉卿. 网脊衣酸上调p21CIP1蛋白诱导前列腺癌细胞周期阻滞的作用分析[J]. 山东大学学报(医学版), 2013, 51(12): 34-40.
[10]	于张健1，张士宝1，刘庆勇1，阮喜云2，杨广笑3，王全颖3. SAC重组腺相关病毒载体的构建及其对前列腺癌CAM移植瘤的抑制作用[J]. 山东大学学报(医学版), 2012, 50(7): 41-.
[11]	许爱辉1，潘喆2，蒋汉明1，孔峰1，胡志敏3，苑辉卿1. 地前素M抗前列腺肿瘤活性的初步探讨[J]. 山东大学学报(医学版), 2010, 48(5): 18-22.
[12]	陈卫国1，龙慧民2，侯建全1，浦金贤1，严春寅1. Gefitinib对激素非依赖性前列腺癌的治疗及其效应初探[J]. 山东大学学报(医学版), 2010, 48(1): 52-55.
[13]	吉恺,孔峰,沈涛,王小玲,许爱辉,苑辉卿,张秀田 . 没药倍半萜成分的分离鉴定及抗肿瘤活性[J]. 山东大学学报(医学版), 2008, 46(4): 344-348.
[14]	王小玲,孔峰,许爱辉,吉恺,蔡捷,任凯,苑辉卿 . 没药倍半萜抑制前列腺癌细胞的增殖活性初探[J]. 山东大学学报(医学版), 2007, 45(12): 1189-1192.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed